2022
Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer
Han R, Yang H, Li Y, Ling C, Lu L. Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer. Medical Oncology 2022, 39: 213. PMID: 36175803, PMCID: PMC9522682, DOI: 10.1007/s12032-022-01814-9.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCaspase 3Histone Deacetylase InhibitorsHistone DeacetylasesHumansMaleMicePentanoic AcidsProstateProstatic NeoplasmsConceptsProstate cancer cellsProstate cancerHDAC3 inhibitorCancer cellsCancer-related deathAnti-cancer effectsVivo mouse modelAnti-cancer efficacyAnti-cancer activityMouse modelNew agentsSecond causeHDAC inhibitorsCancerNormal cellsInhibitorsValeric acidCellsCASP3 activityCulture systemDiseaseChemosensitizers
2011
Risk of second primary cancer after treatment for esophageal cancer: a pooled analysis of nine cancer registries
Zhu G, Chen Y, Zhu Z, Lu L, Bi X, Deng Q, Chen X, Su H, Liu Y, Guo H, Zheng T, Yu H, Zhang Y. Risk of second primary cancer after treatment for esophageal cancer: a pooled analysis of nine cancer registries. Diseases Of The Esophagus 2011, 25: 505-511. PMID: 22067063, DOI: 10.1111/j.1442-2050.2011.01273.x.Peer-Reviewed Original ResearchConceptsStandardized incidence ratiosEsophageal cancer survivorsSecond primary cancerSecond cancersEsophageal cancerPrimary cancerCancer survivorsProstate cancerCancer riskEnd Results ProgramEsophageal cancer patientsAssociation of radiotherapySecond cancer riskMost risk estimatesCancer RegistryIncidence ratiosDecreased riskPatient survivalResults ProgramPooled analysisCancer patientsLung cancerClinical trialsSecondary cancersGeneral population